Stock analysts and investors use these public quarterly reports to assess the financial health of a company and estimate its ...

ArriVent ended Q1 with $326.4 million of cash and extended its expected runway from Q3 2027 to Q4 2027, reducing near-term ...

On track to report initial safety, PK and early activity fromPhase 1 dose-escalation trial of STRO-004, potential best-in-class Tissue Factor ADC, in mid-2026 - ...

Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors Streng ...

What's at stake for President Trump's political influence in Tuesday's primaries in Indiana and Ohio? NPR's Leila Fadel asks Jessica Taylor of the Cook Political Report.

In the trial’s first day of testimony, Elon Musk said greed led co-founder Sam Altman to pull the A.I. lab away from its nonprofit roots. OpenAI says that’s nonsense. By Cade Metz and Mike Isaac ...

SAN FRANCISCO — It’s a trial so unusual, not even artificial intelligence could make it up. Subscribe to read this story ad-free Get unlimited access to ad-free articles and exclusive content. Jury ...

1. Before reading the full paper, we would of course want to read the abstract. However, I would never base my clinical decisions based on the abstract alone. I read the abstract only on two occasions ...

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

Learn how a general ledger supports double-entry accounting, compiling vital transaction data for accurate financial reporting and analysis.

An FDA review of records in the U.S. clinical trials database shows that results have not been reported for 30% of clinical studies, the agency said on Monday. To remedy this shortfall, the U.S.

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...